Company Profile
Nektar Therapeutics Stock Price, News & Analysis
- Ticker:
- NKTR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
73.45 USD (+0.49%)
Close
Last updated: August 6, 2026
1.98B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, NKTR closed up 0.49% at $73.45. No new same-company headline was identified in the current news window.
Company overview
Immune-Regulatory Therapeutics
Nektar Therapeutics develops biologic medicines that selectively modulate immune-cell pathways. Its current portfolio emphasizes regulatory T-cell biology for autoimmune and inflammatory diseases.
Rezpegaldesleukin
Rezpegaldesleukin is an IL-2 pathway agonist designed to expand and activate regulatory T cells without broadly stimulating conventional effector T cells.
Atopic-Dermatitis Development
The Phase 3 ZENITH-AD program is designed to test rezpegaldesleukin in moderate-to-severe atopic dermatitis after Phase 2b results showed responses during treatment and follow-up.
Alopecia-Areata Development
The REZOLVE-AA program evaluates rezpegaldesleukin in severe alopecia areata, including whether treatment effects persist during an off-treatment observation period.
Type 1 Diabetes and Earlier Pipeline
Rezpegaldesleukin is also being studied in a TrialNet-sponsored Phase 2 type 1 diabetes trial. Nektar's earlier portfolio includes TNFR2-directed antibodies such as NKTR-0165.
Future catalysts
FDA end-of-Phase 2 meeting for rezpegaldesleukin in alopecia areata in the second quarter of 2026.
Initiation of the Phase 3 ZENITH-AD program by July 2026.
REZOLVE-AA 24-week off-treatment data in the fourth quarter of 2026.
REZOLVE-AD 52-week off-treatment data in the first quarter of 2027.
Initial data from a TrialNet-sponsored Phase 2 type 1 diabetes study in 2027.
Recent news
- 01
- 02
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Nektar Therapeutics
- 03
- 04
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
Source: Nektar Therapeutics
- 05
Nektar Therapeutics Reports First Quarter 2026 Financial Results
Source: Nektar Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Nektar Therapeutics (NKTR)?
Nektar Therapeutics (NKTR) most recently closed at 73.45 USD, a +0.49% move versus the previous session.
What is the market cap of Nektar Therapeutics (NKTR)?
Nektar Therapeutics currently has a market capitalization of 1.98B USD on BioPharmSignal.
What does Nektar Therapeutics do?
Immune-Regulatory Therapeutics Nektar Therapeutics develops biologic medicines that selectively modulate immune-cell pathways. Its current portfolio emphasizes regulatory T-cell biology for autoimmune and inflammatory diseases. Rezpegaldesleukin Rezpegaldesleukin is an IL-2 pathway agonist designed to expand and activate regulatory T cells without broadly...
On which exchange is NKTR stock listed?
Nektar Therapeutics (NKTR) is associated with NASDAQ, United States, Biopharma.
What is IL-2?
Rezpegaldesleukin Rezpegaldesleukin is an IL-2 pathway agonist designed to expand and activate regulatory T cells without broadly stimulating conventional effector T cells.
Which conditions is Nektar Therapeutics targeting with IL-2?
Nektar Therapeutics is associated with diabetes based on its company overview and current catalyst commentary.
How does Nektar Therapeutics describe recent progress with IL-2?
FDA end-of-Phase 2 meeting for rezpegaldesleukin in alopecia areata in the second quarter of 2026. Initiation of the Phase 3 ZENITH-AD program by July 2026. REZOLVE-AA 24-week off-treatment data in the fourth quarter of 2026. REZOLVE-AD 52-week off-treatment data in the first quarter of 2027. Initial data from a TrialNet-sponsored Phase 2 type 1 diabetes...
What is ZENITH-AD?
Atopic-Dermatitis Development The Phase 3 ZENITH-AD program is designed to test rezpegaldesleukin in moderate-to-severe atopic dermatitis after Phase 2b results showed responses during treatment and follow-up.